Industrial music for a cancer cure

[unixronin]

Cancer has taken many loved ones away from us. Metropolis Records, in association with Distortion Productions presents a five disc box set of exclusive tracks by some of the biggest names in the industrial genre to raise money for cancer research. Cancer survivor and long time promoter and DJ, Jim Semonik has assembled 83 artists from around the world. The boxset includes 4 cds and a downloadable 5th disc when you purchase the physical edition.

This compilation contains 83 tracks in total, including new exclusive tracks and mixes by Combichrist, 16 Volt, Assemblage 23, Suicide Commando, Noisuf-X, Chemlab, Cesium 137, Stromkern, Imperative Reaction, Rein[Forced], System Syn and many more.

Packaged in a DVD style digipak containing the four physical CDs and the dropcard for the "Bonus Medication" disc 5 digital download. Proceeds will be donated to the Foundation for Cancer Research and Wellness.

Limited edition of 2500.  Go here for the details.  Pass the word around.

Comments

this might sound cold hearted . . .

[lebo-superman.livejournal.com]

but I think this fundraiser for Cancer Research is part of the national Health Care problem.

In a nutshell - it's at least possible that doing research has become so lucrative that the incentive to actually cure diseases has been lost. It's not so well known, but a documented fact, that the AMA's own charter says it exists to "guarantee the profitability of the practice of medicine" within the USA. If there was no profit to doing the research, but the pharma companies were allowed to profit off of working products brought to market, we might see a dramatic increase in the number of products being brought to market that actually cure diseases. Just a guess.

Re: this might sound cold hearted . . .

[unixronin.livejournal.com]

I think you're conflating multiple things there. There is no profit to be made from any medical research that doesn't yield a marketable cure or treatment. In fact, that's related to one allegation being leveled at pharma companies — that they're not doing enough research into treating or curing extremely rare or primarily-tropical diseases, because in the first case there aren't enough potential patients to make it profitable, and in the second the potential patients are too poor to make it profitable.